- Ticker
- ABIO
- Price
- 3.00
- Stock movement down
- -0.09 (-2.91%)
- Company name
- ARCA Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 43.23M
- Ent value
- 2.20M
- Price/Sales
- -
- Price/Book
- 1.04
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -53.56%
- 1 year return
- 53.85%
- 3 year return
- -6.41%
- 5 year return
- -11.80%
- 10 year return
- -35.53%
Last updated: 2024-04-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.04 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 14.41M |
| EPS (TTM) | -0.69 |
| FCF per share (TTM) | -0.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -10.60M |
| Net income (TTM) | -9.93M |
| EPS (TTM) | -0.69 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 42.45M |
| Net receivables | 0.00 |
| Total current assets | 42.70M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 43.09M |
| Accounts payable | 334.00K |
| Short/Current long term debt | 280.00K |
| Total current liabilities | 1.13M |
| Total liabilities | 1.41M |
| Shareholder's equity | 41.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.91M |
| Capital expenditures (TTM) | 2.00K |
| Free cash flow (TTM) | -10.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -23.82% |
| Return on Assets | -23.04% |
| Return on Invested Capital | -23.82% |
| Cash Return on Invested Capital | -26.19% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.06 |
| Daily high | 3.10 |
| Daily low | 2.95 |
| Daily Volume | 601K |
| All-time high | 5726700.00 |
| 1y analyst estimate | 7.00 |
| Beta | 1.46 |
| EPS (TTM) | -0.69 |
| Dividend per share | - |
| Ex-div date | 1 May 2006 |
| Next earnings date | 22 Apr 2024 |
Downside potential
Loading...
Downside potential data
| ABIO | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.85% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 2 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -94.12% | -11.35% |
| Avg time to new high | 292 days | 13 days |
| Max time to new high | 6071 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
43.23M
Marketcap category
Small-cap
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Michael R. Bristow
Country
USA
City
Westminster
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page